Evaxion A/S Files 6-K Report

Ticker: EVAX · Form: 6-K · Filed: 2025-10-17T00:00:00.000Z

Sentiment: neutral

Topics: reporting, foreign-private-issuer, sec-filing

TL;DR

Evaxion A/S filed a 6-K on Oct 17, 2025, confirming it's a foreign private issuer filing 20-F.

AI Summary

Evaxion A/S, a biotechnology company, filed a Form 6-K on October 17, 2025. The filing is a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F. The company's principal executive office is located in Hoersholm, Denmark.

Why It Matters

This filing provides routine updates for investors regarding Evaxion A/S's status as a foreign private issuer and its reporting obligations.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of a foreign private issuer filed with the SEC to provide information that the company has made or is required to make public pursuant to the laws of its home country or that it has filed or is required to file with a stock exchange on which its securities are traded.

What does it mean that Evaxion A/S is a 'foreign private issuer'?

A foreign private issuer is a foreign entity that is not a government, and it is generally subject to different SEC reporting requirements than domestic U.S. companies.

What is the significance of the filing date?

The filing date of October 17, 2025, indicates when this specific report was submitted to the SEC.

Where is Evaxion A/S's principal executive office located?

Evaxion A/S's principal executive office is located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

Does this filing indicate Evaxion A/S files annual reports under Form 20-F?

Yes, the filing explicitly indicates by check mark that the registrant files annual reports under cover of Form 20-F.

From the Filing

0001171843-25-006500.txt : 20251017 0001171843-25-006500.hdr.sgml : 20251017 20251017083029 ACCESSION NUMBER: 0001171843-25-006500 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20251017 FILED AS OF DATE: 20251017 DATE AS OF CHANGE: 20251017 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 251399034 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 f6k_101725.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On October 17, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K. Exhibits Exhibit No.   Description       99.1   Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed

View on Read The Filing